MACBETH. Phase IV Study to evaluate the efficacy of aflibercept in subjects with neovascular Age-related Macular Degeneration (wAMD), without optimal response to repeated monthly intravitreal injections of Anti Vascular Endothelial Growth Factor (Anti VEGF-A) Therapy 19/03/2014

Study to evaluate the efficacy of aflibercept in subjects with neovascular Age-related Macular Degeneration (wAMD), without optimal response to repeated monthly intravitreal injections of Anti Vascular Endothelial Growth Factor (Anti VEGF-A) Therapy. Patients with neovascular age-related macular degeneration who do not respond to usual treatment with conventional medications may respond to a new drug of the same class which is designed to block a larger fraction of proangiogenic factors

If you are interested in taking part in a clinical trial, please call us at 935 950 155 and we will assess whether you are eligible. Further information on trials at research projects

Author

Dr. Jordi Monés, M.D., Ph.D.
COMB Medical license number: 22.838
Director
Doctor of Medicine and Surgery
Specialist in Ophthalmology
Specialist in Retina, Macula and Vitreorretinal